obovatol profile

Obovatol is a natural product isolated from the leaves of *Olea europaea* (olive tree). It exhibits various biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Its synthesis involves complex multi-step reactions starting from readily available starting materials. Obovatol is studied due to its potential therapeutic applications, particularly in the treatment of inflammatory diseases and cancer. Its antioxidant activity is attributed to its ability to scavenge free radicals and protect cells from oxidative damage. The compound's anticancer activity is associated with its ability to inhibit cell proliferation and induce apoptosis in cancer cells.'

obovatol: antineoplastic agent from Magnolis obovata; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	100771
CHEMBL ID	491809
SCHEMBL ID	454929
MeSH ID	M0111768

Synonym
obovatol
83864-78-2
nsc-364150
nsc364150
1,2-benzenediol, 5-(2-propenyl)-3-(4-(2-propenyl)phenoxy)-
5-prop-2-enyl-3-(4-prop-2-enylphenoxy)benzene-1,2-diol
CHEMBL491809
obovator
h6szx78nxa ,
4',5-diallyl-2,3-dihydroxybiphenyl ether
unii-h6szx78nxa
nsc 364150
SCHEMBL454929
obvatol
5-allyl-3-(4-allylphenoxy)benzene-1,2-diol
Q15634039
DTXSID601003992
5-(prop-2-en-1-yl)-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol
AC-36774
1,2-benzenediol, 5-(2-propenyl)-3-[4-(2-propenyl)phenoxy]-
5-(2-propen-1-yl)-3-[4-(2-propen-1-yl)phenoxy]-1,2-benzenediol
AKOS040760602
FS-8182

Research Excerpts

Effects

Obovatol has various biological activities, including anti-proliferative, neurotrophic, anti-fibrillogenic and anti-platelet. It also has been reported biological activities such as muscle relaxative,Anti-gastric ulcer and Anti-allergic activities.

Excerpt	Reference	Relevance
"Obovatol has a potent antithrombotic effect, which may be due to antiplatelet activity. "	( Antiplatelet activity of obovatol, a biphenolic component of Magnolia Obovata, in rat arterial thrombosis and rabbit platelet aggregation. Hong, JT; Kwon, BM; Lee, SH; Lim, Y; Park, ES; Yoo, HS; Yun, YP, 2011)	2.12
"Obovatol has a potent antithrombotic effect, which may be due to antiplatelet activity. "	( Antiplatelet activity of obovatol, a biphenolic component of Magnolia Obovata, in rat arterial thrombosis and rabbit platelet aggregation. Hong, JT; Kwon, BM; Lee, SH; Lim, Y; Park, ES; Yoo, HS; Yun, YP, 2011)	2.12
"Obovatol has various biological activities, including anti-proliferative, neurotrophic, anti-fibrillogenic, anti-platelet, anti-fungal and anti-inflammatory activities. "	( JJK694, a synthesized obovatol derivative, inhibits platelet activation by suppressing cyclooxygenase and lipoxygenase activities. Jung, JK; Kim, TJ; Lee, JJ; Lee, MY; Ma, JY; Min, YK; Yu, JY; Yun, YP, 2012)	2.14
"Obovatol has been reported biological activities such as muscle relaxative, anti-gastric ulcer, anti-allergic and anti-bacterial activities. "	( Anti-platelet activity of diacetylated obovatol through regulating cyclooxygenase and lipoxygenase activities. Jung, JK; Kim, TJ; Lee, JJ; Lee, MY; Ma, JY; Min, YK; Yu, JY; Yun, YP, 2012)	2.09

Treatment

Obovatol (10, 15, 20, 25 microM) inhibits cancer cell growth in the absence or the presence of tumor necrosis factor-alpha (TNF-alpha , 10 ng/ml) and tetradecanoyl phorbol acetate (TPA 10 or 50 nM) in a concentration-dependent manner through induction of apoptotic cell death. Treatment blocked the cell cycle in G1 phase by down-regulating the expression of cyclins and CDKs.

Excerpt	Reference	Relevance
"Obovatol was treated to macrophages with inflammasome triggers, and secretions of interleukin (IL)-1β, IL-18, and caspase-1 were measured as readouts of inflammasome activation. "	( Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation. Ahn, H; Han, BC; Jung, EM; Kang, SG; Kim, J; Kim, JC; Lee, GS; Lee, J; Lee, SH; Shin, H; Yang, H, 2019)	3.4
"The obovatol-treated groups (100 microg and 1mg: 0.14+/-0.04 and 0.09+/-0.03 mm2, respectively) showed significant reduction in neointimal formation versus the control group (0.17+/-0.02 mm2)."	( Obovatol from Magnolia obovata inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing p21Cip1. Hong, JT; Kim, DW; Kwon, BM; Kwon, JS; Lee, JJ; Lee, SH; Lim, Y; Park, RK; Yoo, HS; Yun, YP, 2010)	2.28
"Treatment with obovatol blocked the cell cycle in G1 phase by down-regulating the expression of cyclins and CDKs, and selectively up-regulating the expression of p21Cip1, a well-known CDK inhibitor."	( Obovatol from Magnolia obovata inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing p21Cip1. Hong, JT; Kim, DW; Kwon, BM; Kwon, JS; Lee, JJ; Lee, SH; Lim, Y; Park, RK; Yoo, HS; Yun, YP, 2010)	2.14
"Treatment of obovatol (10, 15, 20, 25 microM) inhibits cancer cell growth in the absence or the presence of tumor necrosis factor-alpha (TNF-alpha , 10 ng/ml) and tetradecanoyl phorbol acetate (TPA 10 or 50 nM) in a concentration-dependent manner through induction of apoptotic cell death."	( Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Hong, JT; Jung, JK; Lee, BS; Lee, SY; Moon, DC; Song, HS; Yoon, DY; Yuk, DY, 2008)	0.99

Toxicity

Excerpt	Reference	Relevance
" Their conditioned media were toxic to SH-SY5Y cells."	( Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage. Kwon, BM; Lee, M; McGeer, E; McGeer, PL; Suk, K, 2012)	0.77

Pharmacokinetics

Excerpt	Reference	Relevance
" On this basis, the chemical components of XECQ were targeted and enriched by network pharmacology, to screen the main pharmacodynamic substances of XECQ in the treatment of acute upper respiratory tract infection in children and discuss the mechanism of action."	( [Pharmacodynamic substances and mechanism of action of Xiaoer Chiqiao Qingre Granules in treatment of acute upper respiratory tract infection in children]. Feng, L; Jia, XB; Liu, J; Lu, GZ; Yang, YJ; Zhao, J; Zhu, MM; Zhu, XJ, 2022)	0.72

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathway	Proteins	Compounds
chitin biosynthesis	16	40

Bioassays (41)

Assay ID	Title	Year	Journal	Article
AID387407	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, ip after 21 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387419	Antitumor activity against human SW620 cells at 30 uM after 96 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387431	Antiproliferative activity against human DLD1 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387438	Cell cycle arrest in human SW620 cells assessed as accumulation at S phase at 50 uM after 72 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387428	Toxicity in SW480 cells xenografted nude mouse assessed as change in body weight 5 mg/kg/day, ip after 21 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387435	Antiproliferative activity against human PC-3 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387447	Induction of apoptosis in human SW620 cells assessed as necrosis relative to control	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387426	Antitumor activity against human SW620 cells at 100 uM after 72 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387439	Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 50 uM after 72 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387411	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, po after 5 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID1279207	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Anti-inflammatory neolignans from the roots of Magnolia officinalis.
AID387433	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387418	Antitumor activity against human SW620 cells at 30 uM after 72 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387429	Antiproliferative activity against human HCT 116 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387442	Induction of apoptosis in human MDA-MB-231 cells assessed as morphological changes in presence of N-acetyl-cysteine after 24 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387423	Antitumor activity against human SW620 cells at 50 uM after 96 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387424	Antitumor activity against human SW620 cells at 100 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387425	Antitumor activity against human SW620 cells at 100 uM after 48 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387412	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, po after 10 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387446	Induction of apoptosis in human SW620 cells assessed as apoptotic cell form at 50 uM relative to control	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387422	Antitumor activity against human SW620 cells at 50 uM after 72 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387413	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, po after 16 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID1279204	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Anti-inflammatory neolignans from the roots of Magnolia officinalis.
AID387437	Cell cycle arrest in human SW620 cells assessed as accumulation at G1 phase at 50 uM after 72 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387441	Induction of apoptosis in human MDA-MB-231 cells assessed as ROS production after 24 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387417	Antitumor activity against human SW620 cells at 30 uM after 48 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387432	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387416	Antitumor activity against human SW620 cells at 30 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387427	Antitumor activity against human SW620 cells at 100 uM after 96 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387436	Antiproliferative activity against human K-562 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387430	Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387443	Cell cycle arrest in human SW620 cells assessed as accumulation at subG1 phase at 50 uM after 72 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387421	Antitumor activity against human SW620 cells at 50 uM after 48 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387414	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, po after 23 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387420	Antitumor activity against human SW620 cells at 50 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387440	Induction of apoptosis in human SW620 cells assessed as chromosomal DNA fragmentation at 50 mM after 48 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387683	Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387445	Effect on apoptosis-mediated morphological changes in human SW620 cells assessed as round cell formation	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387408	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor weight at 5 mg/kg/day, ip after 21 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID387415	Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 5 mg/kg/day, po after 27 days	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis.
AID1279208	Induction of ferricytochrome c reduction in human neutrophils by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Anti-inflammatory neolignans from the roots of Magnolia officinalis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.56)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (28.21)	29.6817
2010's	22 (56.41)	24.3611
2020's	5 (12.82)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (5.13%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	37 (94.87%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.03	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
phenol [no description available]	7.06	1	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.21	1	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
dapi DAPI: RN given refers to parent cpd.	2.05	1	indoles	fluorochrome
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.03	1	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	7.05	1	barbiturates	GABAA receptor agonist
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.03	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	3.16	1	catechin	antioxidant; plant metabolite
bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.	2.04	1	diatomic bromine
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.04	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
alkenes [no description available]	2.04	1
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.08	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	3.16	1	D-glucopyranose	epitope; mouse metabolite
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.16	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
magnolol [no description available]	2.75	3	biphenyls
honokiol [no description available]	2.97	4	biphenyls
asiaticoside [no description available]	2.21	1
gastrodin gastrodin: the glucoside of 4-hydroxybenzyl alcohol (gastrodigenin); isolated from Gastrodia elata Blume;	3.16	1	glycoside
astragaloside a [no description available]	2.21	1
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.05	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
4-methoxyhonokiol 4-methoxyhonokiol: an NSAID isolated from Magnolia obovata; structure in first source	2.48	2
sorafenib [no description available]	2.13	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
gingerol gingerol: an active ingredient in GINGER along with SHOGAOL. a nonvolatile methoxy phenyl decanone. gingerol : A beta-hydroxy ketone that is 5-hydroxydecan-3-one substituted by a 4-hydroxy-3-methoxyphenyl moiety at position 1; believed to inhibit adipogenesis. It is a constituent of fresh ginger.	3.16	1	beta-hydroxy ketone; guaiacols	antineoplastic agent; plant metabolite
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	3.37	6
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.06	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	3.16	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	3.16	1	stilbene
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	3.16	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.08	1
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.03	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	3.16	1
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.07	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
daidzein [no description available]	2.21	1	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
12-hydroxy-5,8,10,14-eicosatetraenoic acid 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)	2.07	1
beta-escin [no description available]	2.21	1
mannich bases Mannich Bases: Ketonic amines prepared from the condensation of a ketone with formaldehyde and ammonia or a primary or secondary amine. A Mannich base can act as the equivalent of an alpha,beta unsaturated ketone in synthesis or can be reduced to form physiologically active amino alcohols.	2.25	1
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.41	1
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.17	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.03	1
longikaurin a longikaurin A: from Isodon adenolomus; structure in first source	2.41	1	kaurane diterpenoid	metabolite

Condition	Relationship Strength	Studies
Colorectal Cancer [description not available]	7.04	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.04	1
Infections, Respiratory [description not available]	3.33	4
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	3.33	4
Fibroid [description not available]	7.25	1
Cancer of the Uterus [description not available]	2.25	1
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	7.25	1
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.25	1
Extravascular Hemolysis [description not available]	2.15	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.15	1
Carcinoma, Epidermoid [description not available]	2.17	1
Cancer of the Tongue [description not available]	2.17	1
Invasiveness, Neoplasm [description not available]	2.17	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.17	1
Tongue Neoplasms Tumors or cancer of the TONGUE.	2.17	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.79	3
Primary Peritonitis [description not available]	2.21	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.21	1
Bone Loss, Osteoclastic [description not available]	2.1	1
Granulocytic Leukemia [description not available]	2.1	1
Acute Disease Disease having a short and relatively severe course.	2.1	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.1	1
Carcinoma, Non-Small Cell Lung [description not available]	2.13	1
Cancer of Lung [description not available]	2.13	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.13	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.13	1
Cancer of Colon [description not available]	2.45	2
Cancer of Prostate [description not available]	2.45	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.45	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.45	2
Disease Exacerbation [description not available]	2.05	1
Innate Inflammatory Response [description not available]	3.67	3
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	8.67	3
Degenerative Diseases, Central Nervous System [description not available]	3.38	2
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	3.38	2
Brain Inflammation [description not available]	2.98	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.98	1
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	2.98	1
Blood Clot [description not available]	2.06	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	7.06	1
Age-Related Memory Disorders [description not available]	2.07	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.07	1
Acute Confusional Senile Dementia [description not available]	2.07	1
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.07	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.07	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.03	1

obovatol

Description

Cross-References

Synonyms (23)

Research Excerpts

Effects

Treatment

Toxicity

Pharmacokinetics

Pathways (1)

Bioassays (41)

Research

Studies (39)

Market Indicators

Research Demand Index: 21.37

Study Types

obovatol

Description

Cross-References

Synonyms (23)

Research Excerpts

Effects

Treatment

Toxicity

Pharmacokinetics

Pathways (1)

Bioassays (41)

Research

Studies (39)

Market Indicators

Research Demand Index: 21.37

Study Types

Related Drugs (40)

Related Conditions (46)